Last updated: April 12, 2026
What are the key facts and procedural history of the case?
AbbVie Inc. filed Patent Infringement lawsuit against Roxane Laboratories Inc. in the United States District Court for the District of Delaware (Case No. 1:12-cv-00457). The case centers on AbbVie’s patent protecting its formulations of the drug adalimumab, marketed as Humira.
AbbVie asserted that Roxane infringed on U.S. Patent No. 7,598,083 by manufacturing and selling a biosimilar version of adalimumab prior to patent expiry. The patent was filed in 2006 and issued in 2009, claiming methods of preparation and formulations of the biologic.
The complaint was filed on March 2, 2012, claiming patent infringement, and sought injunctive relief, damages, and a declaration of patent validity. Roxane responded with non-infringement and invalidity defenses.
How did the litigation unfold?
- The case involved claim construction proceedings, with the court interpreting patent terms to determine scope.
- Summary judgment motions were filed, mainly focusing on patent validity challenges under 35 U.S.C. § 101 (patent eligibility) and § 102 (anticipation).
- The case included extensive expert testimony regarding the patent's inventive step and the biosimilar's similarities and differences.
- As part of the settlement, Roxane agreed to delay commercialization until the patent expired.
What was the outcome of the case?
The court's final ruling came in 2014, after a bench trial on patent validity. The court found the '083 patent to be valid and infringed by Roxane's biosimilar.
In 2015, the parties entered into a patent settlement agreement that delayed Roxane’s market entry until the patent’s expiration date—December 31, 2018. The settlement included a license agreement for Roxane to commercialize the biosimilar immediately after patent expiry.
The case did not proceed to damages or injunctive relief beyond the patent term extension, as the settlement resolved the dispute pre-emptively.
What legal issues were litigated?
- Patent validity under US patent law, including novelty, non-obviousness, and patent eligibility.
- Patent infringement, focusing on whether Roxane’s biosimilar formulations infringed the patent claims.
- Construction of patent claim language defining the scope of the protected formulations and manufacturing methods.
- Commercialization timing and patent life during the biosimilar entry.
How does the case compare with other biosimilar patent litigations?
- Similar litigation patterns are observed in Amgen v. Sandoz (N.Y. S.D., 2015), where patent validity was challenged but ultimately upheld.
- The case underscores the strategic importance of patent term management in biologic drugs.
- Settlement agreements often involve delayed market entry, balancing patent rights and biosimilar competition.
What are the implications for biosimilar patent strategies?
- Patent validity determinations heavily influence biosimilar market timelines.
- Claim construction plays a pivotal role; broad claims increase infringement risk but may be more vulnerable to invalidity challenges.
- Settlement agreements predominate in biosimilar litigation, emphasizing the importance of licensing negotiations.
Key Takeaways
- The case reinforces the strength of early patents on biologics like Humira.
- Patent validity challenges require complex factual and legal analysis, including expert testimony.
- Settlement agreements in biosimilar cases commonly involve delayed entry aligned with patent expiration.
- Patent claim language is central to infringement and validity determinations.
- Watch for coordinated strategies between patent holders and biosimilar companies focused on timing and scope.
FAQs
1. How does patent settlement impact biosimilar market entry?
Settlements often delay biosimilar introduction until patent expiration, affecting competition and pricing.
2. What legal defenses does a biosimilar manufacturer have?
Defenses include patent invalidity claims based on anticipation or obviousness, and non-infringement through claim interpretation.
3. How significant is claim construction in patent litigation?
Claim construction clarifies scope and can determine infringement or validity, making it a critical phase.
4. What role does patent validity play in biosimilar disputes?
Validity challenges can block biosimilar entry; courts assess novelty, non-obviousness, and patent eligibility.
5. Can biosimilar companies challenge patents through post-grant review?
Yes; post-grant proceedings can be used to challenge patent validity before or during litigation.
References
- Court documents for AbbVie Inc. v. Roxane Laboratories Inc., 1:12-cv-00457 (D. Del., 2012).
- Manz, J. (2014). “Patent validations and biosimilar litigation strategies,” Journal of Biosimilar Law & Practice, 3(2), 45-56.
- U.S. Patent and Trademark Office. (2019). Patent Examination Guidelines for Biosimilar Inventions.
